Expanded Access RBS2418 Treatment

$0.00

Clinical Trial Record

Return to Clinical Trials

Study Start

N/A

Primary Completion

N/A

Study Completion

N/A

Enrollment

N/A

Study Overview

Expanded Access RBS2418 Treatment

This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.

Given lack of any therapeutic options such as standard of care chemotherapy for this single patient owing to lack of tolerability and opportunity to enroll in any clinical trial due to extent of disease, patient desires to try compassionate use protocol with RBS2418, an oral immunotherapeutic agent that is currently in clinical trials and is well tolerated by patients. Furthermore, patient's tumor has been shown to express ENPP1, the protein targeted by RBS2418

Expanded Access in Pancreatic Cancer

DRUG: RBS2418

RBS2418-EA-002

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2022-12-26	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2024-02-18
First Submitted that Met QC Criteria 2022-12-26	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2024-02-21
First Posted (ACTUAL) 2023-01-13	Results First Posted N/A	Last Verified 2024-02

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
FEMALE

Sexes Eligible for Study:

Accepts Healthy Volunteers:

The patient is willing and able to provide informed consent. Only the patient for whom this clinical study/experimental treatment was designed will be given the investigational drug under the treatment of the PI. No other patient is authorized to participate in or to receive treatment under this treatment protocol.

Not applicable

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Dr. Bertrand Tuan

Investigators

PRINCIPAL_INVESTIGATOR: Bertrand Tuan, MD, Pacific Hematology and Oncology Associates

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record